Anxiety Disorder & Depression Treatments Market: Introduction
Depression and anxiety are common forms of psychiatric disorders which are prevalent among a large chunk of the population. Major depression of depressive disorders is a diagnosable condition that is classified as a mood disorder and its effects can be a long-term issue with symptoms such as reduced energy, overwhelming sadness, loss of appetite, and low interest on things. Depression, if left untreated can result in severe health complications and is considered to be life-threatening. Types of depression include persistent depressive disorder, bipolar disorder, seasonal depression, postpartum depression and psychotic depression among others.
Request for a sample copy of this report @ https://www.insightsandreports.com/request-sample/56
Market Dynamics
Global anxiety disorder & depression treatments market is majorly driven by the rising number of people with severe anxiety and depression at the global level. According to the World Health Organization, approximately 300 million people across the globe suffer from depression. Further, according to Insights and Reports, in 2017, more than 10 million residents in the U.S. experienced incidences of depression which resulted in severe impairment. Further, according to the Anxiety & Depression Association of America, more than 40 million residents in the U.S. aged 18 and above, which is equivalent to 18.1% of the overall population of the country suffer from anxiety disorders each year. These factors have paved the way for anxiety disorder and depression treatments market.
Product Insights
Based on product type, anti-depressant drugs accounted for the major share of global anxiety disorder & depression treatments market in 2017, the growth of which is majorly attributed to the influx of advanced techniques to counter mental illness coupled the rising use of an antidepressant in depressive disorder treatment. Moreover, antidepressant drugs are widely used in several anxiety disorders such as traumatic stress, panic disorder, phobia, and others.
Disorder Insights
On the basis of disorder types, Major Depressive Disorder (MDD) is anticipated to hold prime share in the global anxiety disorder and depression treatments market, primarily owing to the rising incidences of this disorder, making it a common type disorder. According to the National Institute of National Health, more than 16.2 million adults in the U.S. suffered from at least one type of MDD in 2016. Therefore, rising cases of MDD would lead to nudge the global anxiety disorder & depression treatments market in the coming decade.
Regional Analysis
North America dominated the global anxiety disorder & depression treatments market in 2017 and is expected to retain market dominance throughout the forecast period. This is primarily owing to the huge chunk of the population in the U.S. are currently suffering from anxiety disorders. According to the Anxiety and Depression Association of America, 40 million adults in the U.S. are affected every year whereby making it a most common type disorder. The treatment for this disorder in the U.S. such as several antidepressant drugs is readily available on prescription.
The Asia Pacific, however, is gaining rapid prominence in the global anxiety disorder & depression treatments market on account of rising working population and busier lifestyles of the younger populace. India and China are the frontrunners to the growth of this industry in the Asia Pacific. According to the Associated Chambers of Commerce and Industry of India, approximately 42% of the employees working in the Indian corporate sector were found to be suffering from depression in 2015, which marked an approximate of 40% growth over the last 8 years. These are some of the factors resulting in a high demand for anxiety disorder & depression treatments market in the country.
Competitive Landscape
Some of the key players operating in the global anxiety disorder & depression treatments market include GlaxoSmithKline Plc, AstraZeneca Plc, El Lily & Company, Johnson & Johnson Inc., and H Lundbeck A/S among others.
Mergers and acquisition, product development and launch, investments are some of the key strategies adopted by the numerous companies in the global anxiety disorder & depression treatments market to grab a strong foothold. For instance, in May 2018, H Lundbeck announced the approval made on the supplemental new drug for Trintellix by U.S. Food and Drug Administration (FDA) to be used for the patients suffering from the major depressive disorder (MDD), majorly owing to its positive effect on processing speed.
For more information about this report @ https://www.insightsandreports.com/industry-reports/anxiety-disorder-and-depression-treatments-market
About Us:
Insights and Reports is a research and consulting group assisting the clients with 360-degree insights with real time qualitative and quantitative information. The Insights and Reports team is valued for continuous client-oriented services. Our data scientists monitor the markets pertaining to their expertise on a daily basis with the help of 150+ analysts to back them with accurate market studies.
Contact Us:
Mr.Saby
Insights And Reports,
2201 Cooperative Way #600,
Herndon, VA 20171, USA.
Tel: +1 703 574 4447
Email:[email protected]
Hi! I am a robot. I just upvoted you! I found similar content that readers might be interested in:
https://www.insightsandreports.com/industry-reports/anxiety-disorder-and-depression-treatments-market
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit